It has been exactly one year! Cannot thank these amazing folks enough. Here is to another year of fun doing science and hopefully many more 🍺

Excited to share that I'll be starting a group D-BSSE, ETH Zurich researching at the intersection of protein design, biology and AI. Come join us! x.com/ETH_en/status/…

Our first paper is out in Cell! Led by Rohith Rajasekaran, we present a programmable reaction-diffusion system that generates synthetic protein waves, oscillations, and patterns for spatiotemporal circuit design and FM data-encoding in human cells. authors.elsevier.com/a/1iN8ZL7PXmeeN

Can the intrinsic physics of multicomponent systems show neural network like computation? Out now: nature.com/articles/s4158… Led by Constantine Evans w/ Jackson O'Brien, Erik Winfree. U Chicago summary: news.uchicago.edu/story/uchicago…

Love the Zelda reference

A bit late to this, but thank you Damon Runyon Cancer Research Foundation for the continued support, and Mo Khalil & ElowitzLab for your generous letters!

Exciting news: AlphaFold 3 has been announced and will be published in 6 months.

Arjun Raj Mark Budde (hiring wetlab, DMs open) 🦕🏆 Uri Alon In case it's helpful to anyone, I posted the evolving set of talk tips that I share with my lab on our website. Scroll to bottom of this page: elowitz.caltech.edu/teaching. (It was once "10 commandments" but has since expanded to 25...the slide titles are currently number 5)

So well deserved!

Excited to announce our new #proteindesign strategy for allosterically controlling the kinetics of protein-protein interactions! Read on for cool applications in cytokine signaling, biosensing, and protein circuits. biorxiv.org/content/10.110…

🚨NEW PUBLICATION ALERT🚨: In a paper out today in Science Magazine we describe a way to build synthetic phosphorylation circuits with customizable sense-and-response functions in human cells. Check it out at science.org/doi/10.1126/sc…. 🧵1/n

LIDAR is out! rdcu.be/efugD We've improved a lot, e.g., making MESA-like LIDAR work, RNAseq of on-/off-target editing, and optimizing RNA delivery. We are one baby step closer to making it useful for therapeutics. NIH high-risk high-reward program provides key support.